Showing results (131-140 of 157) with videos related to
Sort By:
Pageof 16
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.Clinical Lung Cancer|April 15, 2018
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 TrialsYi-Long Wu, Lecia V Sequist, Eng-Huat Tan, et al.Nature Medicine|April 29, 2025
D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trialByoung Chul Cho, Shun Lu, Myung Ah Lee, et al.Lung Cancer (Amsterdam, Netherlands)|December 15, 2020
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)Shun Lu, Jie Wang, Ying Cheng, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M Awad, Giulia C Leonardi, Sasha Kravets, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2025
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN StudyYi-Long Wu, Hye Ryun Kim, Ross A Soo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 12, 2022
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)Sai-Hong Ignatius Ou, Makoto Nishio, Myung-Ju Ahn, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 7, 2024
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON TrialSolange Peters, Byoung Chul Cho, Alexander V Luft, et al.JTO Clinical and Research Reports|May 24, 2023
Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLCQing Zhou, Ross A Soo, Gee-Chen Chang, et al.Pageof 16